首页> 外文OA文献 >Research on allergic rhinitis improvement in asthmatic children after dust mite exposure reduction: a randomized, double-blind, cross-placebo study protocol
【2h】

Research on allergic rhinitis improvement in asthmatic children after dust mite exposure reduction: a randomized, double-blind, cross-placebo study protocol

机译:粉尘螨暴露后哮喘儿童过敏性鼻炎改善研究:随机,双盲,跨安慰剂研究方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Abstract Background Allergic rhinitis (AR) in children is a major respiratory inflammatory disease with a high incidence that is increasing yearly. In China, 54.93% of children with asthma have AR, which often requires synchronous treatment. House dust mites (HDMs) are common allergens that often cause attacks of AR and asthma. Reducing allergen exposure is one of the most important measures to control and treat AR and asthma attacks. Hestelia Mite Bait, containing 0.1% emamectin, is a new tool for trapping and killing dust mites, reducing the number of dust mites on mattresses and thereby potentially reducing stimulation by allergens and ultimately improving asthma and rhinitis symptoms. This single-centre, randomized, double-blind, cross-placebo trial will explore the improvement in AR in asthmatic children after dust mite exposure reduction. Methods We will recruit 60 children (aged 3–12 years) who have been diagnosed with AR and asthma and are allergic to dust mites as confirmed by a serum allergen test. Participants will randomly receive the Hestelia Mite Bait intervention for 8 weeks and the placebo intervention for 8 weeks. There will be a 4-week washout period between the two interventions. The primary outcome is the visual analogue scale (VAS) score of AR symptoms; the secondary outcomes include the Rhinitis Control Assessment Test (RCAT) score, Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score, changes in the dust mite level, drug usage for asthma and AR, Asthma Control Questionnaire-5 (ACQ-5) score, and frequencies of acute asthma attacks, emergency visits, and hospitalizations. Discussion This study aims to scientifically and objectively evaluate the effects of mite bait on rhinitis and asthma improvement after dust mite exposure reduction and provides a convenient means for future prevention and treatment of allergic diseases involving the airways in children. Trial registration www.chictr.org.cn ChiCTR1900024688. Registered on July 21, 2019
机译:摘要背景患儿过敏性鼻炎(AR)是一种主要的呼吸炎症疾病,发病率高,每年增加。在中国,54.93%的哮喘儿童具有AR,通常需要同步治疗。房屋尘螨(HDMS)是常见的过敏原,通常会导致AR和哮喘的攻击。减少过敏原暴露是控制和治疗AR和哮喘发作的最重要措施之一。 Heestelia螨虫诱饵含有0.1%的Emamectin,是一种用于捕获和杀死灰尘的新工具,减少床垫上的灰尘数,从而可能降低过敏原的刺激并最终改善哮喘和鼻炎症状。这种单中心,随机,双盲,交叉安慰剂试验将在尘埃螨暴露后探讨哮喘儿童的AR中的改善。方法我们将招募60名儿童(年龄龄3-12岁),他被诊断出患有AR和哮喘,并且通过血清过敏原试验证实的粉尘对粉尘过敏。参与者将随机接受Hestelia螨虫干预8周和安慰剂干预8周。两个干预措施之间将有4周的洗涤期。主要结果是AR症状的视觉模拟量表(VAS)得分;二次结果包括鼻炎对照评估试验(RCAT)得分,鼻咽炎质量调查问卷(RQLQ)评分,尘埃螨虫的变化,哮喘和AR的药物用法,哮喘控制问卷-5(ACQ-5)得分,和急性哮喘攻击,紧急访问和住院的频率。讨论本研究旨在科思地和客观地评估粉尘螨暴露后螨虫病和哮喘改善的螨虫病和哮喘改善的影响,为未来预防和治疗涉及儿童气道的过敏性疾病的方便手段。试用注册www.chictr.org.cn chictr1900024688。 2019年7月21日注册

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号